Immunomonitoring reveals interruption of anergy after vaccination in a case of type-2-papillary renal cell carcinoma

PMID: 28303767
Journal: Immunotherapy (volume: 9, issue: 4, Immunotherapy 2017 03;9(4):319-329)
Published: 2017-03-01

Clavijo-Salomon MA, Bergami-Santos PC, M Barbuto JA


With the enormous and growing interest in the clinical application of immunotherapy, we are currently facing the need to accurately monitor the immune function of cancer patients. Here, we describe changes in the immune status of a patient with metastatic type-2-papillary renal cell carcinoma, before and after surgery and subsequent immunotherapy with a dendritic cell-tumor cell hybrid vaccine. Through the accurate assessment of monocyte-derived dendritic cells (Mo-DCs) function, we show that Mo-DCs were freed from tumor-induced maturation blockage by tumor resection surgery, while Mo-DCs-tumor induced suppression and anergy were only interrupted by the vaccination treatment. Our data suggest that the evaluation of Mo-DCs‘ function may provide a powerful and precise tool to monitor immune restoration in cancer patients.